Research - Medical Research Institute of New Zealand

In 2001 the Medical Research Institute of New Zealand (MRINZ) was established as an independent medical research organisation. Under the direction of Professor Richard Beasley, it has become internationally recognised as one of New Zealand's major medical research organisations, publishing innovative research in high impact international journals.

The Institute has developed research programmes in the fields of alcohol and drug abuse, asthma, COPD, medical education, pharmacovigilance, stroke/rehabilitation, Māori and Pacific health, and venous thromboembolism (DVT). Significant advances have been made in each of these fields with exciting programmes in place for future work.

Based primarily in Wellington, MRINZ conducts research throughout New Zealand with collaborators in Dunedin, Christchurch, Hastings, Hamilton, Tauranga and Auckland.

Stroke Rehabilitation in Māori & Pacific Islanders

Stroke research

As one of the major causes of death and disability in ageing populations, the impact of stroke is increasing. Stroke is the third highest contributor to mortality in New Zealand. As the population ages, stroke numbers and mortality will continue to increase.

Perhaps more importantly, the consequences for survivors of stroke are considerable. Stroke is a particular problem for Māori and Pacific people in New Zealand. Drs Harry McNaughton and Matire Harwood are currently undertaking a large randomised clinical trial of different rehabilitation programmes for stroke recovery in Māori and Pacific people.

This programme, funded by the Health Research Council of New Zealand, is one of the largest studies ever attempted globally in stroke rehabilitation.

Magnesium Treatment for Asthma and Emphysema

Giving magnesium through a nebuliser

Magnesium is a mineral with many functions in the human body. It is sometimes given by injection into the vein to treat severe asthma attacks. MRINZ is currently running two studies based in the emergency departments of Wellington and Hutt Hospitals to find out if magnesium can be given by nebuliser instead of injection. One study will look at patients with severe asthma and the other will include patients with emphysema. The magnesium is given through a nebuliser, along with normal medicines, and patients will be followed to see if their lung function and symptoms improve more quickly.

This study is very important for the thousands of asthma and emphysema patients in the country because magnesium is a safe and inexpensive treatment that could have a significant impact on their treatment in emergency situations.

More details can be found at the Institute's website, including details of requirements for volunteers for the many other studies the Institute is undertaking.

Related Links

• Medical Research Institute of NZ website

Department Details:
Marketing